← Back to Search

Lifestyle Changes + Metformin for Diabetes Prevention (DPPOS Trial)

Phase 3
Waitlist Available
Led By Kishore Gadde, MD
Research Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participation as a volunteer in the Diabetes Prevention Program (DPP)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.
Awards & highlights
Pivotal Trial

Summary

This trial looks at the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population. Lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.

Who is the study for?
This trial is for volunteers who were part of the Diabetes Prevention Program, focusing on those at high risk due to impaired glucose tolerance. It's particularly aimed at understanding long-term health outcomes in diverse populations, including a significant minority representation.
What is being tested?
The study tests the long-term effects of lifestyle interventions and metformin on preventing diabetes. DPPOS-3 specifically looks into how these approaches impact cardiovascular disease and cancer risks as the participant group ages.
What are the potential side effects?
While specific side effects are not listed here, generally, lifestyle changes may include diet and exercise adjustments with minimal risk. Metformin can cause stomach upset, diarrhea, or other gastrointestinal issues in some individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020.
This trial's timeline: 3 weeks for screening, Varies for treatment, and outcomes were assessed in visit years starting in 2010, 2012, 2017, 2020. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Development of Diabetes.
Major Adverse Cardiovascular Events (MACE): Myocardial Infarction (MI), Stroke, or Cardiovascular Death (CVD)
Prevalence of Aggregate Microvascular Complication
+1 more
Secondary study objectives
Cognitive Function
Frailty
Mortality
+2 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: 1 Original LifestyleActive Control3 Interventions
randomized to unmasked Intensive Lifestyle during the DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle plus DPPOS Boost Lifestyle sessions in DPPOS Phase 1 and 2
Group II: 2 Original MetforminActive Control3 Interventions
randomized to the masked metformin treatment group during DPP and continued open label in DPPOS. Participants were also offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2.
Group III: 3 Original PlaceboPlacebo Group2 Interventions
randomized to masked placebo during DPP and offered Intensive Lifestyle Group Session, DPPOS Group Lifestyle in DPPOS Phase 1 and 2

Find a Location

Who is running the clinical trial?

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead Sponsor
2,464 Previous Clinical Trials
4,334,674 Total Patients Enrolled
109 Trials studying Diabetes
138,677 Patients Enrolled for Diabetes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,068 Previous Clinical Trials
2,744,675 Total Patients Enrolled
5 Trials studying Diabetes
2,288 Patients Enrolled for Diabetes
National Institute on Aging (NIA)NIH
1,804 Previous Clinical Trials
28,192,120 Total Patients Enrolled
27 Trials studying Diabetes
767,049 Patients Enrolled for Diabetes
National Institute on Minority Health and Health Disparities (NIMHD)NIH
444 Previous Clinical Trials
1,410,729 Total Patients Enrolled
16 Trials studying Diabetes
15,963 Patients Enrolled for Diabetes
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,943 Previous Clinical Trials
47,795,114 Total Patients Enrolled
31 Trials studying Diabetes
52,445 Patients Enrolled for Diabetes
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,109,308 Total Patients Enrolled
7 Trials studying Diabetes
28,779 Patients Enrolled for Diabetes
National Eye Institute (NEI)NIH
558 Previous Clinical Trials
1,405,692 Total Patients Enrolled
2 Trials studying Diabetes
2,190 Patients Enrolled for Diabetes
National Center for Research Resources (NCRR)NIH
539 Previous Clinical Trials
314,323 Total Patients Enrolled
3 Trials studying Diabetes
47 Patients Enrolled for Diabetes
Office of Research on Women's Health (ORWH)NIH
32 Previous Clinical Trials
33,332 Total Patients Enrolled
1 Trials studying Diabetes
5,145 Patients Enrolled for Diabetes
Centers for Disease Control and PreventionFED
892 Previous Clinical Trials
21,997,983 Total Patients Enrolled
3 Trials studying Diabetes
17,225 Patients Enrolled for Diabetes

Media Library

DPPOS Group Lifestyle Clinical Trial Eligibility Overview. Trial Name: NCT00038727 — Phase 3
Diabetes Research Study Groups: 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
Diabetes Clinical Trial 2023: DPPOS Group Lifestyle Highlights & Side Effects. Trial Name: NCT00038727 — Phase 3
DPPOS Group Lifestyle 2023 Treatment Timeline for Medical Study. Trial Name: NCT00038727 — Phase 3
~120 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top